WebCHO-M Selexis SURETechnology™ CHO-S and CHO-K1 GS Our competitive timeline can be as fast as 12 weeks from transfection to fully characterized RCB. Our platforms express a diverse range of molecules with high titers, including mAbs, bispecifics, Fc-fusions, recombinant proteins, ADCs, enzymes, glycoprotein vaccines, and biosimilars.
Biosimilar Development Services & Products Similis Bio JSR Life …
WebCellosaurus SURE CHO-M (CVCL_R728) Group: Patented cell line. Group: Serum/protein free medium cell line. Biotechnology: Used for high yield production of therapeutic proteins and antibodies (Selexis). Doubling time: 15.7 hours (Selexis). Omics: Genome sequenced. WebDec 20, 2024 · The Selexis SURE CHO-M Cell Line is a proprietary high-performance mammalian cell line that is derived from CHO-K1 cells and used for the production of therapeutic recombinant proteins and monoclonal antibodies. The growth and production properties of the Selexis SURE CHO-M Cell Line are well defined, and the feed strategy … csir chemical science
Turgut Ilaclari A.S. And Selexis SA Sign Service And Commercial ...
WebSep 17, 2024 · Selexis SA, a JSR Life Sciences Company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. WebFeb 26, 2024 · The Selexis SURE CHO-M Cell Line is a proprietary high-performance mammalian cell line that is derived from CHO-K1 cells and used for the production of therapeutic recombinant proteins and monoclonal antibodies. The growth and production properties of the Selexis SURE CHO-M Cell Line are well defined, and the feed strategy … WebQuestion: Can Selexis conduct genomic characterization to support RCB generation? Answer: Yes, Selexis has one of the most comprehensive genomic characterization platforms in the industry. Selexis ... marchtozion.com